About Rosa & Co

Dr. Beaver has over 25 years of experience in the drug–disease modeling industry. Prior to creating Rosa & Co. in 2002, Dr. Beaver collaborated with a global pharmaceutical firm to structure their open-source drug development group. In 1997, Dr. Beaver cofounded Pharsight Consulting Services, a first-generation pharmaceutical modeling company that drove large-scale adoption of leading-edge drug–disease modeling worldwide. Previously, Dr. Beaver was a principal of Pope Street Group (PSG), a management consultancy and venture incubator firm. PSG incubated StarMine, a unique quantitative-modeling financial services company (subsequently acquired by Thomson Reuters). Prior to PSG, Dr. Beaver was an associate at Strategic Decisions Group (SDG). In the early 1990s, he closely observed the advancement of predictive biosimulation software which led to the spin-off of Entelos, Inc., the first-generation PhysioPD-style company (acquired by Rosa in 2014). Dr. Beaver holds a PhD in Engineering from Stanford University and a BA from Simpson College, on whose Board of Trustees he served.

Dr. Friedrich brings over 17 years of leadership expertise in applying mathematical models of biologic/physiologic systems for overcoming development challenges faced by pharmaceutical and consumer product companies. At Rosa (and previously at Entelos, Inc.), she has developed significant experience in the fields of diabetes, blood disorders, CNS disorders, oncology, immuno-oncology, rheumatoid arthritis, respiratory diseases, skin diseases, gastrointestinal disorders, and other immune system dysfunctions and inflammatory processes. While at Rosa, Dr. Friedrich developed and published the first peer-reviewed journal article on the qualification of mechanistic mathematical models. Before Rosa, Dr. Friedrich was the Director of Core Product Development at Entelos, Inc., the first-generation leader in PhysioPD-style models. Dr. Friedrich has spearheaded numerous modeling methodologies and contributed to foundational patents, including on the use of virtual patients and populations to explore biological variability and uncertainty, and on the identification of biomarkers. Dr. Friedrich completed her BS at MIT and a PhD in Management Science and Engineering at Stanford University.

Dr. Reed brings 15 years of experience managing large-scale strategic collaborations with client pharmaceutical and consumer product organizations. At Rosa (and previously at Entelos, Inc.), his areas of expertise include metabolic diseases, oncology, central nervous system diseases, and inflammation/immunology. His efforts focus on trial design, target evaluation, competitive differentiation, and novel biomarkers, and has led to several patents and publications. Dr. Reed’s work has been presented at dozens of scientific conferences worldwide. Prior to his position at Entelos, Dr. Reed held positions in preclinical pharmacology and drug development at Shaman Pharmaceuticals Inc. and Tularik Inc. (acquired by Amgen Inc.). His contributions include the development of novel animal models for type 2 diabetes. Dr. Reed completed his BS in Biology and MA in Exercise Physiology at The University of Texas at Austin, and a PhD in Exercise Physiology at The Ohio State University. He completed his postdoctoral fellowship at Stanford University, which focused on the mechanistic evaluation of insulin resistance in animal models.

For over 24 years, Mr. Schneider has been working with life science organizations at all stages of the drug development pipeline. By asking questions and bringing insights, he has developed trusting relationships with clients attempting to make the best decisions with the most relevant data. Prior to joining Rosa in 2023, Mr. Schneider has sold reagents, instrumentation and services in a variety of markets including microscopy, image analysis, tissue diagnostics, immuno-assays, DNA synthesis and genome engineering. Mr. Schneider holds an S.M. in Biology from MIT and a B.S. in Biochemistry from the University of Rochester in NY.